PharmNovo, a clinical-stage pharmaceutical company dedicated to developing breakthrough treatments for neuropathic pain, has successfully raised an impressive $110,000,000 in funding. The company's focus on addressing the current lack of effective therapies in this field has garnered significant attention. PharmNovo's lead drug candidate, PN6047, has shown promising results in reducing neuropathic pain in animal models, with Phase I trial data indicating its safety and tolerability at tested doses, without the typical adverse effects associated with conventional opioids. This latest funding round will propel the company into Phase II trials for PN6047, bolstering its potential to revolutionize the treatment landscape for neuropathic pain. With its unique mechanism of action targeting the delta opioid receptor, PharmNovo is poised to make a significant impact in alleviating pain for patients in need.
PharmNovo Announces $110 Million in Funding for Promising Neuropathic Pain Drug Candidate PN6047: Phase II Ready!
Recently funded 路 $110.0MHealthcare
Get the full PharmNovo company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
